Wüst H J, Lennartz H
Department of Surgery, University Hospital of Düsseldorf, West Germany.
Proc R Soc Med. 1977;70 Suppl 1(Suppl 1):18-9. doi: 10.1177/00359157770700S106.
Based on our experience with our first patients, miconazole is now the drug of choice in cases of systemic and pulmonary candidal infection. Initially we prefer the parenteral route of administration which is continued for only one or two weeks after a negative finding in culture. The dosage is 1.2 g per day for a 70 kg patient. Thereafter the treatment is continued orally for another four weeks. Miconazole is well documented as a drug without serious side-effects, but the incidence of candidal infections in about 1% of our surgical patients does not justify its prophylactic administration. Like antibiotics, miconazole is given only when there is a clinical manifestation and a positive finding in culture.
根据我们对首批患者的治疗经验,咪康唑现已成为系统性和肺部念珠菌感染病例的首选药物。起初,我们更倾向于采用肠胃外给药途径,在培养结果呈阴性后仅持续一到两周。对于一名70公斤的患者,剂量为每天1.2克。此后,口服治疗再持续四周。咪康唑作为一种无严重副作用的药物有充分的文献记载,但在我们约1%的外科手术患者中念珠菌感染的发生率并不支持对其进行预防性给药。与抗生素一样,仅在有临床表现且培养结果呈阳性时才使用咪康唑。